All In Biotech

Drug Trial Radar · NCT05727891

Evaluation of Tonabersat for DME

A Phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

May 2, 2023

Primary completion

Jan 15, 2026

Study completion Jan 15, 2026

Sponsor

Lead sponsor
Jaeb Center for Health ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.

Conditions

  • Diabetic Macular Edema

Interventions

  • TonabersatDrug

    Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.

  • PlaceboOther

    Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Optical Coherence Tomography Central Subfield Thickness Change From BaselineTime frame: 6 months

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Associates of Southern California

    Huntington Beach, California

  • Loma Linda University

    Loma Linda, California

  • East Bay Retina Consultants, Inc.

    Oakland, California

  • Southern California Desert Retina Consultants, Inc.

    Palm Desert, California

  • Macula Retina Vitreous Institute

    Torrance, California

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • University of Florida- Jacksonville

    Jacksonville, Florida

  • Central Florida Retina Institute

    Lakeland, Florida

  • Florida Retina Consultants

    Lakeland, Florida

  • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas

    Pinellas Park, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Thomas Eye Group

    Sandy Springs, Georgia

  • Illinois Retina Associates

    Oak Park, Illinois

  • Midwest Eye Institute

    Indianapolis, Indiana

  • Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana

    West Monroe, Louisiana

  • Elman Retina Group

    Baltimore, Maryland

  • Boston Medical Center Corporation

    Boston, Massachusetts

  • Joslin Diabetes Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Retina Research Institute, LLC

    St Louis, Missouri

  • Retina-Vitreous Surgeons of Central NY, PC

    Liverpool, New York

  • Verum Research LLC

    Eugene, Oregon

  • The Trustees of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Pittsburg Clinical Trial Consortium

    Sewickley, Pennsylvania

  • Hilton Head Retina Institute

    Hilton Head Island, South Carolina

  • Retina Consultants of Texas, PA

    Bellaire, Texas

  • Texas Retina Associates

    Lubbock, Texas

  • Retinal Consultants of Texas

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.